China Nuokang Bio-Pharmaceutical Inc. to Report Third Quarter 2012 Financial Results

BEIJING, Nov. 5, 2012 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company plans to release third quarter 2012 financial results on Sunday, November 25, 2012 .

The Company will hold a conference call at 8:00 a.m. ET on Monday, November 26 to discuss third quarter 2012 results. Listeners may access the call by dialing:

United States toll free: 1-855-500-8701
China toll free: 400-1200654
Hong Kong toll free: 800-903737
United Kingdom toll free: 0800-0159724
International: 65-6723-9385
Conference ID: 64309501

A live webcast and replay of the earnings call will be available through the Company's website

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 4,200 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share; Kaitong®, a lipid emulsion alprostadil product for the treatment of peripheral vascular diseases, cardiocerebral microcirculation disorders and post-surgery thrombosis; and alpha lipoic acid capsules, or ALA, an antioxidant product that addresses diabetic neuropathy. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit for more information.

CONTACT: China Nuokang Bio-Pharmaceutical Inc. Mr. Steven Duan Vice President of Investor Relations Email: ICR, Inc. Mr. Rob Koepp Tel: (+86) 10-6583-7516 or (646) 405-5180 Email: robert.koepp@icrinc.comSource:China Nuokang Bio-Pharmaceutical Inc.